Jeffrey Bennett, MD

Clinical Psychiatrist
Psychiatry
Accepting new patients
Call for an appointment
or

    About me

    Dr. Jeffrey I. Bennett joined the faculty at Southern Illinois University School of Medicine as an Assistant Professor of Psychiatry and Director of the Department of Psychiatry Residency Program in 2003.  He has since held several posts (Director, Division of Developmental Disabilities; Psychiatry Clerkship Director, and Director, Division of Adult Services).  In 2014, he became the Donnelly Family Endowed Professor in Developmental Disabilities and subsequently an SIU SOM Academy Scholar 2015.

    Dr. Bennett completed medical school at New York University School of Medicine (1986) followed by a one-year Research Fellowship in Neurology at the University of Maryland Medical Center in Baltimore (1987). He completed his Psychiatry Residency at the University of Chicago (1991) after a medical internship at Michael Reese Hospital.  He subsequently finished a one year Fellowship in Neuropsychiatry (1992), becoming faculty at the University of Chicago (1993-2003).  He earned his bachelor's degree at Harvard University in Cambridge, Massachusetts (1978) followed by a year as a Research Associate in the Neurobiology Division at the University of California, San Francisco with Michael Dennis, Steve Hauser, and Leah Ziskind-Conhaim.

    While an Instructor at the University of Chicago, he also served as a Neuropsychiatric Consultant for Tinley Park Mental Health Center and Midwest Neurological Rehabilitation Center in Waterford, Wisconsin (1992-93). He also consulted for W.A. Howe Development Center in Tinley Park, Illinois (1992-94).  He served as Medical Director at Jacksonville Developmental Center (2011-2012).

    He is board certified in psychiatry. He currently serves as Immediate Past President for the Illinois Psychiatric Society.  He is a delegate to the Illinois State Medical Society, an Area 4 Representative to the American Psychiatric Association Assembly, and a member of the American Psychiatric Association Telepsychiatry and Membership Committees.  He is a member of American Neuropsychiatric Association, American Medical Association, and Association for Academic Psychiatry.

    Videos

    Remote video URL

    Gender

    Male

    Education & training

    Positions
    Associate Professor of Clinical Psychiatry
    Department of Psychiatry Chair - St. John's Hospital
    Board Certifications
    Psychiatry
    Medical School
    New York University School of Medicine, New York, NY
    Residency
    University of Chicago Hospitals, Chicago, IL - Psychiatry
    Fellowship
    University of Chicago Hospitals, Chicago, IL - Neuropsychiatry
    University of Maryland Medical Center - Neurology Research

    Specialties

    Clinical locations

    Locations

    SIU Psychiatry

    319 E Madison St Springfield, IL 62702 3rd Floor
    Mon - Fri: 8:00 am-4:30 pm

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Research

    Research Interests
    Neuropsychiatric disorders such as intellectual disabilities and neurodevelopmental disorders, dementia, delirium, epilepsy accompanied by psychiatric or behavioral syndromes, behavioral and psychological effects from traumatic brain injury.

    Clinical trials

    Trial
    Psychiatry

    A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real-world effectiveness of deutetrabenazine on the multidimensional impact of TD

    Active recruiting

    What is the effectiveness of deutetrabenazine treatment on the multidimensional impact of TD movements on individuals’ lives?

    Trial
    Psychiatry

    A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

    Active recruiting

    The primary efficacy endpoint is the change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to Day 28 for REL-1017 as compared to placebo.

    Trial
    Psychiatry

    The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes. (The UNCOVER Study)

    Active recruiting

    The primary objective of this study is to collect both active and passive study watch and phone application data, which aims to capture mental health status, in subjects participating in the RECOVER clinical trial (A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression).

    Trial
    Psychiatry

    A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

    Active recruiting

    The primary objective of this study is to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing at least a 50% reduction in baseline depressive symptom severity, based on Montgomery Åsberg Depression Rating Scale (MADRS) total score, at 12 months from randomization.

    Trial
    Psychiatry

    ImpactTD Registry: A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real-world effectiveness of deutetrabenazine on the multidimensional impact of TD

    Active recruiting

    TV50717-CNS-40223: The purpose of this study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life.

    Trial
    Psychiatry

    RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression

    Active recruiting

    The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

    Related articles

    Dr. Kevin Simon

    Simon leads efforts for better behavioral health in Boston

    SIU School of Medicine alumnus Dr. Kevin Simon (’15) was named Boston's first chief behavioral health officer in June 2022. Mayor Michelle Wu appointed Simon to the newly created post and tasked him with developing and implementing a comprehensive behavioral health agenda for the city's most vulnerable.